Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies

Main Article Content

Kim Papp
K. Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada

Jacek C. Szepietowski
Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland

Leon Kircik
Icahn School of Medicine at Mount Sinai, New York, NY, USA

Darryl Toth
XLR8 Medical Research and Probity Medical Research, Windsor, ON, Canada

Michael E. Kuligowski
Incyte Corporation, Wilmington, DE, USA

May E. Venturanza
Incyte Corporation, Wilmington, DE, USA

Kang Sun
Incyte Corporation, Wilmington, DE, USA

Eric L. Simpson
Oregon Health and Science University, Portland, OR, USA

Keywords

Atopic Dermatits, Janus Kinase Inhibitor, Topical, Roxulitinib

Abstract

Abstract not available.

References

1. Wei W, et al. J Dermatol. 2018;45(2):150-157.

2. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121(3):340-347.

3. Bao L, et al. JAKSTAT. 2013;2(3):e24137.

4. Oetjen LK, et al. Cell. 2017; 171(1):217-228.

5. Quintas-Cardama A, et al. Blood. 2010;115(15):3109-3117.

6. Kim BS, et al. J Allergy Clin Immunol. 2020;145(2):572-582.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.95

Article Details

How to Cite
[1]
Papp, K., Szepietowski, J.C., Kircik, L., Toth, D., Kuligowski, M.E., Venturanza, M.E., Sun, K. and Simpson, E.L. 2020. Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s95. DOI:https://doi.org/10.25251/skin.4.supp.95.
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>